To explore the potential of combining galunisertib with sorafenib in HCC cells, cell lines were simultaneously exposed to 0.1, 1, 10, and 100 μM galunisertib with 5 μM sorafenib in presence of TGF-β for 72 hours (Figure 4B). Here, TGFB1 is linked to hepatocellular carcinoma.